Trautwein C, van der Geer P, Karin M, Hunter T, Chojkier M
Department of Medicine (Veterans Affairs Medical Center), University of California, San Diego 92161.
J Clin Invest. 1994 Jun;93(6):2554-61. doi: 10.1172/JCI117266.
LAP (NF-IL6 or C/EBP beta), is a liver transcriptional activator protein that confers liver-specific gene expression. Because LAP has a characteristic phosphoacceptor sequence for cAMP-dependent protein kinase A (PKA), we tested if in vitro phosphorylation of LAP by PKA modulates its interaction with specific DNA sequences. The major PKA phosphorylation site of LAP was identified as Ser105, which is a predicted PKA site. As expected, this PKA phosphorylation site disappears after mutation of Ser105 to Ala. Kinetic studies with LAP and LAP Asp105 (which mimics a phosphoserine residue) demonstrated that phosphorylation of Ser105 itself has no effect on DNA binding. Phosphorylation of other sites by PKA, identified in the region between Ser173 and Ser223 and at Ser240, by analysis of truncated and mutated LAP peptides, resulted in an inhibition of DNA binding. LAP was also phosphorylated by purified protein kinase C in vitro, and the major phosphoacceptor was shown to be Ser240 within the DNA-binding domain of LAP. Phosphorylation of LAP at this residue or introduction of a Ser240 to Asp mutation resulted in marked decrease in its binding to DNA. These results suggest that site-specific phosphorylations of LAP modulate transactivation of its target genes.
肝细胞核因子4α(NF-IL6或C/EBPβ)是一种肝脏转录激活蛋白,可赋予肝脏特异性基因表达。由于肝细胞核因子4α具有依赖于环磷酸腺苷的蛋白激酶A(PKA)的特征性磷酸化位点序列,我们测试了PKA在体外对肝细胞核因子4α的磷酸化是否会调节其与特定DNA序列的相互作用。肝细胞核因子4α的主要PKA磷酸化位点被确定为丝氨酸105,这是一个预测的PKA位点。正如预期的那样,在丝氨酸105突变为丙氨酸后,这个PKA磷酸化位点消失了。对肝细胞核因子4α和肝细胞核因子4α天冬氨酸105(模拟磷酸丝氨酸残基)的动力学研究表明,丝氨酸105本身的磷酸化对DNA结合没有影响。通过对截短和突变的肝细胞核因子4α肽段的分析,在丝氨酸173和丝氨酸223之间的区域以及丝氨酸240处鉴定出PKA对其他位点的磷酸化,导致DNA结合受到抑制。肝细胞核因子4α在体外也被纯化的蛋白激酶C磷酸化,主要的磷酸化位点显示为肝细胞核因子4α的DNA结合结构域内的丝氨酸240。该残基处肝细胞核因子4α的磷酸化或丝氨酸240突变为天冬氨酸导致其与DNA的结合显著减少。这些结果表明,肝细胞核因子4α的位点特异性磷酸化调节其靶基因的反式激活。